Tempus AI expands deals with AstraZeneca and Pathos for $200M, Avidicure raises $50M seed round, Bioxodes reports Phase 2a ...

Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff ...

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

But the company is not ruling out future deals, even in its metabolic unit, which recently saw a major partnership with ...

Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for ...

Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer trials while focusing on immunology leadership ...

Zealand Pharma hires Eli Lilly veteran Utpal Singh as CSO to advance peptide platform, following Roche obesity drug deal and ...

A Bay Area protein design startup wants to build more potent antibody-drug conjugates, and is starting with $20 million in ...

Ascletis Pharma's obesity drug ASC30 shows puzzling results in Phase 1b trial, with high dose less effective than lower doses ...